CLINICAL TRIALS PROFILE FOR IDECABTAGENE VICLEUCEL

All Clinical Trials for idecabtagene vicleucel

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06045806 ↗	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After A	Recruiting	Bristol-Myers Squibb	Phase 3	2023-10-16	The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
NCT06045806 ↗	A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After A	Recruiting	Celgene	Phase 3	2023-10-16	The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
NCT06138275 ↗	Elranatamab in R/R Multiple Myeloma	Recruiting	Pfizer	Phase 2	2024-03-08	This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
NCT06138275 ↗	Elranatamab in R/R Multiple Myeloma	Recruiting	Massachusetts General Hospital	Phase 2	2024-03-08	This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
NCT06179888 ↗	Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma	Recruiting	National Cancer Institute (NCI)	Phase 2	2024-12-30	This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
NCT06185751 ↗	Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma	Not yet recruiting	Paula C. & Rodger O. Riney Blood Cancer Research	Phase 1	2024-06-30	Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.

Clinical Trial Conditions for idecabtagene vicleucel

Condition Name

Condition Name for idecabtagene vicleucel
Intervention	Trials
Multiple Myeloma	6
Refractory Multiple Myeloma	2
Myeloma	1
Relapse Multiple Myeloma	1

Condition MeSH

Condition MeSH for idecabtagene vicleucel
Intervention	Trials
Multiple Myeloma	6
Neoplasms, Plasma Cell	5
Recurrence	1

Clinical Trial Locations for idecabtagene vicleucel

Trials by Country

Trials by Country for idecabtagene vicleucel
Location	Trials
United States	23
France	9
Germany	6
Japan	6
Israel	4

Trials by US State

Trials by US State for idecabtagene vicleucel
Location	Trials
Massachusetts	3
Missouri	2
California	2
North Carolina	2
Minnesota	1

Clinical Trial Progress for idecabtagene vicleucel

Clinical Trial Phase

Clinical Trial Phase for idecabtagene vicleucel
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for idecabtagene vicleucel
Clinical Trial Phase	Trials
RECRUITING	5
Not yet recruiting	1

Clinical Trial Sponsors for idecabtagene vicleucel

Sponsor Name

Sponsor Name for idecabtagene vicleucel
Sponsor	Trials
Bristol-Myers Squibb	3
Celgene	2
Atrium Health Levine Cancer Institute	1

Sponsor Type

Sponsor Type for idecabtagene vicleucel
Sponsor	Trials
Industry	6
Other	6
NIH	1

Clinical Trials, Market Analysis, and Projections for Idecabtagene Vicleucel

Last updated: February 20, 2026

What is the current status of clinical trials for idecabtagene vicleucel?

Idecabtagene vicleucel (brand name: Abecma) is a CAR T-cell therapy targeting BCMA (B-cell maturation antigen) for multiple myeloma. It received FDA approval in March 2021 based on the KarMMa trial, which demonstrated an overall response rate (ORR) of 73%, with 33% achieving complete response (CR) in heavily pretreated patients.

Key Clinical Trial Data:

• FDA Approval: March 2021
• Approval Indication: Relapsed/refractory multiple myeloma after four or more prior therapies.
• Major Trial: KarMMa (NCT03361748)

KarMMa Trial Results:

Parameter	Result
Participants	128 patients
ORR	73%
Complete Response	33%
Median Duration of Response	10.7 months
Median Progression-Free Survival	8.8 months
Overall Survival	Data not mature

Ongoing Clinical Trials:

• KarMMa-2 (NCT04662089): Evaluating idecabtagene vicleucel in earlier lines of therapy.
• KarMMa-3 (NCT05586316): Comparing idecabtagene vicleucel versus standard regimens in second relapse.
• Combining with Other Agents: Trials assessing synergy with daratumumab, pomalidomide, and bortezomib.

Regulatory Status:

• Approved in the U.S. via accelerated approval, with confirmatory trials ongoing.
• Regulatory submissions initiated or planned in Europe, Japan, and China.

What is the market landscape and competitive positioning?

Market Overview:

Multiple myeloma Treatment Market (2023):

• Estimated value: $15 billion
• Projected CAGR (2023-2028): 9%

Idecabtagene vicleucel is one of five CAR T-cell therapies approved for hematologic malignancies, focused on relapsed/refractory multiple myeloma.

Competitors:

Drug	Target	Approval Year	Response Rate	Key Trial
Belantamab mafodotin	BCMA	2020	ORR 31% (monotherapy)	DREAMM-2
Ciltacabtagene autoleucel	BCMA	2022	ORR 98%	CARTITUDE-1
JNJ-68284528 (JNJ CAR T)	BCMA	Under trial	Data pending	Multiple trials

Idecabtagene vicleucel's efficacy (ORR 73%) compares favorably with belantamab mafodotin but lags behind ciltacabtagene autoleucel, which reports ORRs near 98% in early data.

Market Penetration Factors:

• Approval for late-line therapy limits initial patient pool.
• Manufacturing complexity and costs of autologous CAR T therapy challenge scalability.
• Reimbursement landscape is evolving with payer interest in long-term cost offsets.

How does market projection look for idecabtagene vicleucel?

Market Forecast (2023-2030):

• 2023: Sales approx. $300 million, primarily in the U.S.
• 2025: Expected increase to $1.2 billion, driven by broader indications and expanded access.
• 2030: Projected to reach $4.5 billion globally, assuming successful adoption in earlier lines.

Drivers:

• Ongoing clinical trial success in earlier lines.
• Regulatory approvals in additional markets.
• Growing reliance on CAR T-cell therapies for multiple myeloma.
• Shift toward personalized, targeted therapies.

Barriers:

• Production costs exceeding $300,000 per treatment.
• Logistics challenge in cell manufacturing.
• Incidence rate of multiple myeloma (~34,200 new cases annually in the U.S.).
• Competition from emerging therapies and improved standard regimens.

Revenue Assumptions:

• Market share: 30-40% of eligible relapsed/refractory patients by 2027.
• Pricing: Approximate $400,000 per treatment, with potential discounts.
• Reimbursement: Increasing, but varies across markets.

What are the implications for industry stakeholders?

• For Pharma Companies: Investment in manufacturing capacity and post-marketing trials remains crucial.
• For Investors: Growth prospects are significant but tempered by competitive and logistical hurdles.
• For Physicians: Adoption hinges on continued demonstration of durable responses and manageable safety profiles.
• For Regulators: Ongoing data collection will determine full approval and broader indications.

---

Key Takeaways

• Idecabtagene vicleucel has demonstrated promising efficacy in late-line multiple myeloma with an ORR of 73% and a manageable safety profile.
• Market penetration is progressing but limited by manufacturing complexity, high costs, and competitive therapies.
• The drug's market size is expected to grow significantly, reaching over $4 billion globally by 2030, contingent on successful trial outcomes, regulatory approvals, and adoption.
• Competitive landscape favors early success for therapies like ciltacabtagene autoleucel, but idecabtagene vicleucel holds a substantial position due to established efficacy in heavily pretreated populations.
• Continued clinical trial data supporting earlier-line use will be vital for long-term market expansion.

---

FAQs

Q1: When was idecabtagene vicleucel first approved?
A1: It received FDA accelerated approval in March 2021.

Q2: What is the main target of this therapy?
A2: BCMA (B-cell maturation antigen) expressed on multiple myeloma cells.

Q3: How does its efficacy compare to competitors?
A3: It shows an ORR of 73%, which is lower than ciltacabtagene autoleucel but higher than belantamab mafodotin.

Q4: Is idecabtagene vicleucel approved for earlier treatment lines?
A4: Currently approved for heavily pretreated relapsed/refractory multiple myeloma; trials are ongoing for earlier lines.

Q5: What are key challenges to its market growth?
A5: Manufacturing costs, logistics, high treatment prices, and emerging therapies.

---

References

1. National Cancer Institute. (2022). Multiple myeloma statistics. Retrieved from https://www.cancer.gov/types/myeloma
2. Food and Drug Administration. (2021). FDA approves idecabtagene vicleucel for multiple myeloma. FDA Press Release.
3. DataMonitor. (2023). Hematologic Malignancies Market Report.
4. Krishnan, A., et al. (2022). Efficacy of CAR T-cell therapies in multiple myeloma. J Hematol Oncol, 15(1), 128.
5. ClinicalTrials.gov. (2023). Idecabtagene vicleucel trials.